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Abstract 
Synchronous malignancies with an esophageal malignancy are not uncommon. However 
synchronous esophageal and renal cell carcinoma (RCC) is rare with only 11 cases 
reported in the world literature, the esophageal malignancies being adenocarcinomas or 
squamous cell carcinomas. Here, we report the first case of synchronous small cell 
carcinoma (SCC) of the esophagus with a RCC. SCC of the esophagus is an aggressive 
malignancy with poor prognosis constituting 0.8–2.4% of all esophageal malignancies, 
currently treated with induction chemotherapy followed by chemoradiotherapy. Our 
patient underwent chemoradiotherapy for the SCC of the esophagus followed by radical 
nephrectomy for the RCC. He developed metastatic disease and died 8 months after 
diagnosis. Larger case series are required to develop a treatment algorithm for such a 
rare presentation. The key points of this report are: (1) Synchronous RCC with a primary 
esophageal carcinoma is a rare presentation. (2) This is the first described case report of a 
SCC of the esophagus with a synchronous RCC. (3) Overall prognosis in a synchronous 
presentation is determined by the primary esophageal malignancy. (4) Esophageal 
carcinomas with synchronous malignancies have a poorer prognosis compared to 
isolated esophageal carcinoma. 
Introduction 
The occurrence of synchronous malignancies with an esophageal malignancy is 
a well-described phenomenon with an incidence ranging from 3.6 to 27.1%, most 
commonly situated in the upper aero-digestive tract [1]. In world literature, only 11 
cases of synchronous esophageal and renal cell carcinoma (RCC) have been previously  
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described [1–5], the esophageal malignancies being histologic subtype of adenocarcinoma 
or squamous cell carcinoma. Identifying a synchronous RCC is important as this may 
affect the selection of the treatment approach. Radical nephrectomy for the RCC may also 
result in renal dysfunction limiting the chemotherapeutic options for the esophageal 
malignancy. We report the first case of a small cell carcinoma (SCC) of the esophagus 
with synchronous RCC along with a review of treatment modalities based on the available 
literature for synchronous presentation. 
Case Report 
A 61-year-old Hispanic male with a 25 pack year history of smoking presented with a history of 
difficulty in swallowing for both solids and liquids of 2 weeks duration with a 3-day history of food 
getting stuck in his throat on swallowing and having to vomit it up. 
Esophagogastroduodenoscopy demonstrated a 10-cm-long tumor in the esophagus starting 35 cm 
from the upper incisor (fig. 1) and extending down to the gastric cardia. Metastatic work-up with a 
computed tomography (CT) scan of the chest, abdomen and pelvis revealed a heterogeneous mass in 
the region of the gastric fundus and gastroesophageal junction with enlarged perigastric lymph nodes 
along the lesser curvature nodes. Another heterogeneous enhancing, lobulated mass measuring 
5.2 × 4.4 cm was seen involving the lower pole anterior cortex of the right kidney with mild perirenal 
extension. Biopsy of the esophageal mass revealed a SCC of the esophagus (fig. 2), with positive staining 
for synaptophysin and vimentin and negative for chromogranin, cytokeratin, leucocyte common 
antigen and S-100. The esophageal SCC was differentiated from a lung primary based on negative 
staining for thyroid transcription factor-1. A CT-guided biopsy of the renal mass revealed a primary 
RCC of clear and granular cell type, grade 2–3 (fig. 3). The patient underwent further metastatic 
work-up with a bone scan and a CT of the head which showed no evidence of distant metastasis.  
He underwent concomitant chemoradiotherapy for his esophageal cancer with four cycles of 
5-fluorouracil and cisplatin along with 50 Gy of radiotherapy in fractionated doses and esophageal stent 
placement to relieve dysphagia. He then underwent six cycles of chemotherapy with carboplatin and 
etoposide followed by right radical nephrectomy revealing a T3aNxMx grade 3 clear cell type RCC with 
capsular extension but with negative surgical margins. On follow-up CT scan of the abdomen and pelvis 
8 months after the initial diagnosis, multiple soft tissue nodules in the right renal fossa suspicious for 
metastatic disease were seen along with an anterior abdominal wall nodule, enlargement of the psoas 
muscle and periaortic lymphadenopathy. Biopsy of the abdominal wall nodule revealed metastatic SCC. 
His chemotherapy regimen was changed to pemetrexed, but given the extent of metastatic disease and 
after discussion with the patient and his family, he was transferred to hospice care where he 
subsequently died. 
Discussion 
Malignant tumors of the esophagus or gastroesophageal junction and RCC are both 
malignancies which are relatively frequent. Synchronous malignancies have been 
described with an esophageal malignancy ranging up to 27.1% [1]. An exhaustive review 
of the literature using PubMed (www.ncbi.nlm.nih.gov/pubmed) identified 11 reports  
[1–5] of synchronous esophageal and renal malignancies. Since the advent of CT 
scanning as part of the metastatic work-up of esophageal malignancy, De Hingh et al. [1] 
have described a 2.1% (4 out of 192) incidence of synchronous RCC in patients operated 
on for esophageal malignancy. Previous to this, individual case reports of 4 cases of 
esophageal malignancy with synchronous RCC have been reported [2–4]. Three more 
cases of esophageal malignancy with synchronous RCC were identified in a retrospective 
study of 744 patients conducted between 1985 and 1998 by Kumagai et al. [5]. In all these 
cases, the primary malignancy was of adenocarcinoma or squamous cell subtype. Our  
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study is the first one to describe a case of SCC of the esophagus with a synchronous 
primary RCC. 
SCC of the esophagus is a rare and aggressive malignancy with as few as approximately 
450 cases reported in the world literature [6, 7], with an incidence of 0.8–2.4% of all 
esophageal malignancies. The median survival for patients with limited disease is around 
22.3 months (range 6 months to 11.2+ years) and for patients with extensive disease it is 
around 8.5 months (range 1.5 months to 2.2 years) [6]. Currently its pathology and 
treatment is extrapolated from pulmonary SCC. Recent series [6] have demonstrated the 
superiority of using induction chemotherapy followed by chemoradiotherapy without 
surgery in achieving long-term survival, unlike earlier series which advocated a surgical 
approach to SCC.
 Early metastasis is common with SCC, most commonly to the 
periesophageal and mediastinal lymph nodes and to the liver with very poor prognosis 
and a 10% one-year survival.  
In esophageal cancers associated with other primary cancers, the prognosis is primarily 
determined by the esophageal cancer itself with 5-year survival rates significantly worse 
than those of patients with solitary esophageal cancer [5]. It is also important to 
differentiate a renal metastasis from a primary RCC to determine a surgical approach for 
the renal mass. The synchronous occurrence of an esophageal malignancy and an RCC 
could be due to an ingested carcinogen which is excreted by the kidney, exposing both the 
esophagus and the kidney to the carcinogen. Tobacco smoke could be the potential 
carcinogen in our case as the patient had a 25 pack year history of smoking, previously 
known to increase the risk of both extrapulmonary SCCs [8] and renal cancers [9]. 
Previous case series have advocated a simultaneous surgical resection of the esophageal 
malignancy along with the RCC, alternatively to treat the esophageal malignancy first 
followed by delayed treatment of a small RCC [1]. 
Our patient’s esophageal malignancy was of a highly aggressive histological subtype 
with poor prognosis. The approach was chemoradiotherapy for the SCC of the esophagus 
followed by surgical approach for the RCC. Larger case series are required to determine a 
treatment algorithm for a similar presentation of SCC of the esophagus with synchronous 
RCC. 
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Fig. 1. Friable tumor on esophagogastroduodenoscopy 35 cm from the upper incisor. 
 
 
 
Fig. 2. Biopsy of esophageal mass demonstrating SCC at high power magnification. 
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Fig. 3. Biopsy of renal mass demonstrating RCC. 
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